Hong Ma
Chief Tech/Sci/R&D Officer at CARSGEN THERAPEUTICS HOLDINGS LIMITED
Profile
Hong Ma is currently a Member at the American Society of Hematology and a Senior Vice President-Clinical Development at CARsgen Therapeutics Holdings Ltd.
In the past, he worked as a Director-Clinical Development at Bellicum Pharmaceuticals, Inc., Director-Clinical Operations at Endocyte, Inc., and Senior Medical Director at Immatics US, Inc. Dr. Ma holds an MBA degree from the University of Georgia, a graduate degree from Central South University, and an undergraduate degree from Central South University.
Hong Ma active positions
Companies | Position | Start |
---|---|---|
CARSGEN THERAPEUTICS HOLDINGS LIMITED | Chief Tech/Sci/R&D Officer | 2018-07-31 |
American Society of Hematology
American Society of Hematology Miscellaneous Commercial ServicesCommercial Services American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC. | Corporate Officer/Principal | 2015-12-31 |
Former positions of Hong Ma
Companies | Position | End |
---|---|---|
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Chief Tech/Sci/R&D Officer | 2018-07-31 |
BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2016-04-30 |
ENDOCYTE, INC. | Corporate Officer/Principal | 2014-06-30 |
Training of Hong Ma
Central South University | Undergraduate Degree |
University of Georgia | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CARSGEN THERAPEUTICS HOLDINGS LIMITED | Health Technology |
Private companies | 4 |
---|---|
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
American Society of Hematology
American Society of Hematology Miscellaneous Commercial ServicesCommercial Services American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC. | Commercial Services |
- Stock Market
- Insiders
- Hong Ma